April 5, 2023
US FDA IND Application Strategy & Execution
Submitting an IND application to the US FDA is a significant step in the development of a new drug or biologic product. But, are you ready? Attend this seminar to understand how to make sure your next IND meets FDA requirements and gets a “Safe to Proceed” letter from the FDA within 30 days from submission.
US FDA IND Application Strategy & Execution
Submitting an IND application to the US FDA is a significant step in the development of a new drug or...
As the project partner, BLA congratulates Deka Bioscienceson receiving IND may proceed letter for DK210 (EGFR) project
As the project partner, BLA congratulates Deka Bioscienceson receiving IND may proceed letter for DK210 (EGFR) project Gaithersburg, MD (February 05,...
As the project partner, BLA congratulates ImmuneOnco on receiving IND may proceed letter for IMM2520 project
As the project partner, BLA congratulates ImmuneOnco on receiving IND may proceed letter for IMM2520 project Gaithersburg, MD (30 December...